The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma
Open accessAbstract
OBJECTIVE: To examine the potential utility of conventional MRI signs in differentiating pseudoprogression (PsP) from early progression (EP). METHODS: This retrospective study reviewed initial postradiotherapy MRI scans of 321 patients with glioblastoma undergoing chemotherapy and radiotherapy. A total of 93 patients were found to have new or increased enhancing mass lesions, raising the possibility of PsP. Final diagnosis of PsP or EP was established upon review of surgical specimens from a second resection or by clinical and radiologic follow-up. A total of 11 MRI signs potentially helpful in the differentiation between PsP and EP were examined on the initial post-RT MRI and were correlated with the final diagnosis through χ(2) or Fisher exact test. RESULTS: Sixty-three (67.7%) of the 93 patients had EP, of which 22 (34.9%) were diagnosed by pathology. Thirty patients (32.3%) had PsP; 6 (16.7% of the 30) were diagnosed by pathology. Subependymal enhancement was predictive for EP (p = 0.001) with 38.1% sensitivity, 93.3% specificity, and 41.8% negative predictive value. The other 10 signs had no predictive value (p = 0.06-1.0). CONCLUSIONS: Conventional MRI signs have limited utility in diagnosing PsP in patients with recently treated glioblastomas and worsening enhancing lesions. We did not find a sign with a high negative predictive value for PsP that would have been the most useful for the clinical physician. When present, subependymal spread of the enhancing lesion is a useful MRI marker in identifying EP rather than PsP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Cited by
Current Clinical Brain Tumor Imaging
Villanueva-Meyer, J. E., Mabray, M. C., & Cha, S. (2017) · Neurosurgery · doi:10.1093/neuros/nyx103 · Cited by 453
Perfusion MRI: The Five Most Frequently Asked Clinical Questions
Essig, M., Nguyen, T. B., Shiroishi, M. S., Saake, M., Provenzale, J. M., Enterline, D. S., Anzalone, N., Dörfler, A., Rovira, À., Wintermark, M., et al. (2013) · American Journal of Roentgenology · doi:10.2214/ajr.12.9544 · Cited by 344
Pseudoprogression of brain tumors
Thust, S. C., van den Bent, M. J., & Smits, M. (2018) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26171 · Cited by 304
Galldiks, N., Dunkl, V., Stoffels, G., Hutterer, M., Rapp, M., Sabel, M., Reifenberger, G., Kebir, S., Dorn, F., Blau, T., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2959-4 · Cited by 266
van Dijken, B. R. J., van Laar, P. J., Holtman, G. A., & van der Hoorn, A. (2017) · European Radiology · doi:10.1007/s00330-017-4789-9 · Cited by 259
Metadata
- Authors
- Young, R. J., Gupta, A., Shah, A. D., Graber, J. J., Zhang, Z., Shi, W., Holodny, A. I., & Omuro, A. M. P.
- Venue
- Neurology
- Published
- 2011-05-31
- Volume
- 76
- Issue
- 22
- Pages
- 1918-1924
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2108201515
- Cited by
- 195
- References
- 2
- FWCI
- 4.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. https://app.cochat.ai/papers/10.1212/wnl.0b013e31821d74e7
- The paper
- Young, R. J., Gupta, A., Shah, A. D., Graber, J. J., Zhang, Z., Shi, W., Holodny, A. I., & Omuro, A. M. P. (2011). Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology. https://doi.org/10.1212/wnl.0b013e31821d74e7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.